All In Biotech

Drug Trial Radar · NCT02114528

Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

Oct 2014

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
Ottawa Heart Institute Research CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether catheter based ablation is better than conventional anti-arrhythmic drug (AAD) therapy for reducing recurrent shocks in patients with an implantable cardioverter defibrillator (ICD). The second purpose of the study is to determine the safety of catheter-based ablation and the effect on quality of life of patients. The study hypothesis is that catheter ablation is superior to AAD therapy in preventing recurrent ventricular arrhythmia in such subjects. This is a pilot trial which will provide data regarding recruitment potential and the feasibility of conducting a larger trial.

Conditions

  • Ventricular Tachycardia
  • Ventricular Arrhythmia

Interventions

  • Antiarrhythmic Drug TherapyDrug

    Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.

  • Catheter ablationProcedure

    Ventricular tachycardia catheter ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Appropriate ICD therapyTime frame: After 30 day treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.